Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Contact information



Primary contact

Mrs Louisa Little


Contact details

University of Southampton Clinical Trials Unit
Tremona Road
SO16 6YD
United Kingdom
+44 23 8120 5331

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Multi-centre randomised trial of chlorambucil versus chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone b-cell lymphoma of mucosa associated lymphoid tissue (malt lymphoma)



Study hypothesis

The aim of the study is to assess the therapeutic activity and the safety of the combination of chlorambucil and rituximab in mucosa associated lymphoid tissue (MALT) lymphomas and to determine whether the addition of ritxuiamb to chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with chlorambucil alone. Also to compare the anti-tumor activity and safety of rituximab alone versus chlorambucil alone.

Ethics approval

South East Multi-Centre Research Ethics Committee, 30/04/2003 (ref: 03/1/031). Amendment approved on the 30/10/2006.

Study design

Multicentre randomised interventional treatment trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Topic: National Cancer Research Network; Subtopic: Lymphoma; Disease: Lymphoma (non-Hodgkin's)


ARM A: Chlorambucil 6 mg/m2 daily orally (p.o.) for 42 consecutive days (weeks 1 - 6)
ARM B: Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1 - 6) and rituximab 375 mg/m2 intravenous (iv) on days 1, 8, 15, 22 during the first month (4 weekly doses)
ARM C: Rituximab 375 mg/m2 iv on days 1, 8, 15, 22 during the first month (4 weekly doses)

Study entry: single randomisation only

Intervention type



Phase III

Drug names

Chlorambucil, rituximab

Primary outcome measure

Event-free-survival (EFS) (failure or death from any cause) for all patients

Secondary outcome measures

1. Complete and partial remission rates for all patients
2. Response duration (time to relapse or progression) for responder patients
3. Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients
4. Overall survival for all patients
5. Acute and long-term toxicity

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

To be eligible for inclusion in this trial, patients must fulfill all the following criteria:
1. Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site
2. Any stage (Ann Arbor I - IV)
3. Either de novo, or relapsed disease following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma)
4. No evidence of histologic transformation to a high grade lymphoma
5. Measurable or evaluable disease
6. Aged greater than 18 years
7. Life expectancy of at least 1 year
8. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
9. No prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localised non-melanomatous skin cancer
10. No prior chemotherapy
11. No prior immunotherapy with any anti-CD20 monoclonal antibody
12. No prior radiotherapy in the last 6 weeks
13. No corticosteroids during the last 28 days, unless prednisone chronically administered at a dose less than 20 mg/day for indications other than lymphoma or lymphoma-related symptoms
14. No evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhytmias, congestive heart failure or myocardial infarction within 12 months before study entry
15. No evidence of symptomatic central nervous system (CNS) disease
16. No impairment of bone marrow function (white blood cells [WBC] greater than 3.0 x 10^9/L, absolute neutrophil count [ANC] greater than 1.5 x 10^9/L, platelets [PLT] greater than 100 x 10^9/L), unless due to lymphoma involvement
17. No major impairment of renal function (serum creatinine less than 1.5 x upper normal) or liver function (aspartate aminotransferase [ASAT]/alanine aminotransferase [ALAT] less than 2.5 upper normal, total bilirubin less than 2.5 x upper normal), unless due to lymphoma involvement
18. No evidence of active opportunistic infections
19. No known human immunodeficiency virus (HIV) infection
20. No active hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
21. No pregnant or lactating status
22. Appropriate contraceptive method in women of childbearing potential or men
23. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
24. Informed consent must be given according to national/local regulations before randomisation

Participant type


Age group




Target number of participants

Planned sample size: 450

Participant exclusion criteria

Does not meet inclusion criteria

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

MP131, University of Southampton Clinical Trials Unit
SO16 6YD
United Kingdom

Sponsor information


Southampton University Hospitals NHS Trust (UK)

Sponsor details

Tremona Road
SO16 6YD
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type

Research organisation

Funder name

International Extranodal Lymphoma Study Group (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

19/10/2018: Cancer Research UK lay results summary link added to Results (plain English) 12/12/2017: No publications found in PubMed, verifying study status with principal investigator.